Double-Blind, Randomized, Placebo-Controlled, 12-Week Study of the Safety and Efficacy of ATHX-105 Phosphate for the Treatment of Obesity.

Trial Profile

Double-Blind, Randomized, Placebo-Controlled, 12-Week Study of the Safety and Efficacy of ATHX-105 Phosphate for the Treatment of Obesity.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 11 Jun 2015

At a glance

  • Drugs ATHX 105 (Primary)
  • Indications Obesity
  • Focus Therapeutic Use
  • Sponsors Athersys
  • Most Recent Events

    • 10 Mar 2009 Status changed from not yet recruiting to withdrawn prior to recruitment, as reported by ClinicalTrials.gov.
    • 08 May 2008 This trial is expected to begin recruitment in the second half of 2008.
    • 04 Mar 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top